Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2)
CA 2338561 A1 · Owner: Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. · Inventors: Ruhmann, Andreas; Spiess, Joachim
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor type 2 (CRFR2) lacking the 8 to 10 N-, terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vector of the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 23, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 23, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 23, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.